1 December 2025 — The first individuals have begun using lenacapavir for HIV prevention in South Africa as part of a study funded by Unitaid led by Wits RHI at the University of the Witwatersrand. In Brazil, a similar study led by Fiocruz is also underway.
In South Africa, where lenacapavir rollout is planned to start in early 2026, the Wits RHI study will provide the Department of Health with the evidence they need to adapt quickly and in real time as they integrate lenacapavir into existing HIV prevention programs. Insights and tools from the Fiocruz study in Brazil will help guide rollout strategies within the country and across Latin America.
Read the full Unitaid press release here.
SEE ALSO:
- Bhekisisa: South Africa wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch
Source : Unitaid
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.